[A reduced TKI dosage is not associated with loss of activity in EGFR mutated NSCLC patients].

Reinmuth, N

[A reduced TKI dosage is not associated with loss of activity in EGFR mutated NSCLC patients]. [electronic resource] - Pneumologie (Stuttgart, Germany) Sep 2014 - 619-23 p. digital

Publication Type: Clinical Trial; Journal Article

1438-8790

10.1055/s-0034-1377927 doi


Aged
Antineoplastic Agents--administration & dosage
Carcinoma, Non-Small-Cell Lung--diagnosis
Dose-Response Relationship, Drug
ErbB Receptors--antagonists & inhibitors
Female
Humans
Lung Neoplasms--diagnosis
Male
Mutation--genetics
Polymorphism, Single Nucleotide--genetics
Protein Kinase Inhibitors--administration & dosage
Treatment Outcome